2. Cell Cycle/DNA Damage Vitamin D Related/Nuclear Receptor Metabolic Enzyme/Protease
  3. PPAR PERK
  4. Perfluorononanoic acid

Perfluorononanoic acid  (Synonyms: PFNA; Heptadecafluorononanoic acid)

Cat. No.: HY-W203683 Purity: 99.9%
COA
SDS
Handling Instructions Technical Support

Perfluorononanoic acid (PFNA) is an orally active PPARα activator. Perfluorononanoic acid activates PPARα-mediated gene expression, including upregulating target genes associated with lipid metabolism and triglyceride storage. Perfluorononanoic acid exhibits certain developmental and reproductive toxicity. Perfluorononanoic acid causes hepatomegaly in pregnant mice, induces high postnatal mortality in neonatal mice, and leads to dose-dependent delays in eye-opening time and puberty onset in mouse offspring.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Perfluorononanoic acid

Perfluorononanoic acid 화학구조

CAS No. : 375-95-1

사이즈 가격 재고 수량
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 해외재고보유
Solution
10 mM * 1 mL in DMSO 해외재고보유
Solid
500 mg 해외재고보유
1 g   견적 받기  
5 g   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

Perfluorononanoic acid Related Antibodies

Top Publications Citing Use of Products

View All PPAR Isoform Specific Products:

View All Isoforms
PPARα PPARβ/δ PPARγ PPAR PPARδ

  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

Perfluorononanoic acid (PFNA) is an orally active PPARα activator. Perfluorononanoic acid activates PPARα-mediated gene expression, including upregulating target genes associated with lipid metabolism and triglyceride storage. Perfluorononanoic acid exhibits certain developmental and reproductive toxicity. Perfluorononanoic acid causes hepatomegaly in pregnant mice, induces high postnatal mortality in neonatal mice, and leads to dose-dependent delays in eye-opening time and puberty onset in mouse offspring[1][2].

IC50 & Target[2]

PPARα

 

In Vitro

Perfluorononanoic acid (6.25-400 µM; 6-72 h) reduces the viability of differentiated human HepaRG hepatocytes in a concentration- and time-dependent manner[1].
Perfluorononanoic acid (25-200 µM; 24 h) increases intracellular triglyceride levels in differentiated human HepaRG hepatocytes, with a BMC50 of 92 µM, and does not significantly alter intracellular cholesterol levels after 24 h of exposure[1].
Perfluorononanoic acid (100 µM; 24 h) alters the expression of 1024 genes in differentiated human HepaRG hepatocytes, induces pathways associated with tRNA aminoacylation, amino acid transport, and endoplasmic reticulum stress (the PERK/ATF4 signaling pathway), and simultaneously suppresses the cholesterol biosynthesis and glycolysis/gluconeogenesis pathways[1].
Perfluorononanoic acid (12.5-200 µM; 24 h) regulates gene expression in differentiated human HepaRG hepatocytes in a concentration-dependent manner, upregulating PPARα target genes and downregulating ADH4 and cholesterol biosynthesis-related genes[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Perfluorononanoic acid Related Antibodies

Cell Viability Assay[1]

Cell Line: differentiated human HepaRG liver cells
Concentration: 6.25, 12.5, 25, 50, 100, 200, 400 µM
Incubation Time: 6 h, 24 h, 72 h
Result: Reduced viability obviously at 400 µM (6, 24, 72 h), 200 (24, 72 h).

Real Time qPCR[1]

Cell Line: differentiated human HepaRG liver cells
Concentration: 12.5, 25, 50, 100, 200 µM
Incubation Time: 24 h
Result: Caused concentration-dependent increases in expression of PPARα target genes: ANGPTL4 (100, 200 µM), PDK4 (50, 100, 200 µM), PLIN2 (50, 100, 200 µM), and PLIN4 (100 µM), with no significant effect on CPT1A.
Caused concentration-dependent decreases in expression of ADH4 (25, 50, 100, 200 µM) and cholesterogenic genes LSS (12.5, 25, 50, 100, 200 µM), FDPS (25, 50, 100, 200 µM), HMGCR (25, 50, 100, 200 µM), EBP (100, 200 µM), IDI1 (100, 200 µM), and ACAT2 (100, 200 µM).
In Vivo

Perfluorononanoic acid (1-10 mg/kg; oral gavage; gestational days 1-17) causes maternal hepatomegaly, complete fetal resorption at high doses, high postnatal mortality and growth retardation in offspring, and activates hepatic PPARα target genes in CD-1 pregnant mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CD-1 mice (female timed-pregnant; male and female offspring)[2]
Dosage: 1 mg/kg; 3 mg/kg; 5 mg/kg; 10 mg/kg
Administration: oral gavage; daily; gestational day 1-17
Result: Led to maternal weight loss and full litter resorption (10 mg/kg dose).
Induced dose‑dependent maternal and fetal hepatomegaly without affecting implantation or fetal viability (doses ≤5 mg/kg).
Caused 80% neonatal death within postnatal day 10 (5 mg/kg).
Activated PPARα, CAR, and PXR target genes in fetal and neonatal livers, and its accumulation persisted in tissues long after exposure, and surviving offspring showed delayed eye opening and puberty onset.
분자량

464.08

화학식

C9HF17O2
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C(=O)(C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)O
선적

Room temperature in continental US; may vary elsewhere.
보관
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
용액&용해도
In Vitro: 

DMSO : 100 mg/mL (215.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 50 mg/mL (107.74 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1548 mL 10.7740 mL 21.5480 mL
5 mM 0.4310 mL 2.1548 mL 4.3096 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • 몰농도 계산기

  • 농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
순도&문서

Purity: 99.9%

SDS (641 KB)

COA (246 KB) HNMR (89 KB) CNMR (152 KB) GC (215 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 2.1548 mL 10.7740 mL 21.5480 mL 53.8700 mL
5 mM 0.4310 mL 2.1548 mL 4.3096 mL 10.7740 mL
10 mM 0.2155 mL 1.0774 mL 2.1548 mL 5.3870 mL
15 mM 0.1437 mL 0.7183 mL 1.4365 mL 3.5913 mL
20 mM 0.1077 mL 0.5387 mL 1.0774 mL 2.6935 mL
25 mM 0.0862 mL 0.4310 mL 0.8619 mL 2.1548 mL
30 mM 0.0718 mL 0.3591 mL 0.7183 mL 1.7957 mL
40 mM 0.0539 mL 0.2694 mL 0.5387 mL 1.3468 mL
50 mM 0.0431 mL 0.2155 mL 0.4310 mL 1.0774 mL
60 mM 0.0359 mL 0.1796 mL 0.3591 mL 0.8978 mL
80 mM 0.0269 mL 0.1347 mL 0.2694 mL 0.6734 mL
100 mM 0.0215 mL 0.1077 mL 0.2155 mL 0.5387 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Perfluorononanoic acid Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Perfluorononanoic acid375-95-1PFNA Heptadecafluorononanoic acidPPARPERKPeroxisome proliferator-activated receptorsProtein kinase R-like endoplasmic reticulum kinasePKR-like endoplasmic reticulum kinasemouse pupspregnant miceCD-1 micecholesterol biosynthesismouse offspringPERK/ATF4 signalinghuman HepaRG liver cellsPPARαCOS-1 cellsliver cellsInhibitorinhibitorinhibit

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

  

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

도

Country or Region *

      

비고

대량구매 문의

Inquiry Information

상품명:
Perfluorononanoic acid
Cat. No.:
HY-W203683
수량:
MCE Japan Authorized Agent:

고객리뷰

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

상품명

  

Lot #

고객명 *

 

메일주소 *

전화번호

 

Department *

회사명 *

 

Country or Region *

비고

SAFETY DATA SHEET (SDS)

English - EN (641 KB) Français - FR (641 KB) Deutsch - DE (641 KB) Norwegian - NO (641 KB) Español - ES (641 KB) Swedish - SV (641 KB) Italian - IT (641 KB) Korean - KR (641 KB) Portuguese - PT (641 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.